The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.
The British molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.
Proscia said that its partnership with Johns Hopkins, which aims to accelerate research breakthroughs and improve patient outcomes, is one among a number of its recent pathology-related engagements.
In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.
The firm has entered the market in Africa with a new collaboration in Ghana. It is also developing instrument-agnostic STI and liquid biopsy tests.
The team will present the results to the US Food and Drug Administration as part of a 510(k) application in order to commercialize the technology with Biofluidica.
